Genentech Newswire

Genentech Newswire

Comprehensive Real-Time News Feed for Genentech.

Results 1 - 20 of 339 in Genentech

  1. Louis James' Canvest 2015 Stock PicksRead the original story w/Photo

    Wednesday May 27 | Resource Investing News

    Held in Vancouver from May 31 to June 1, the 2015 Canadian Investor Conference was a bit of a different ballgame than it's been in previous years. For one thing, for the second year in a row, the conference included companies focused not only on resources, but also on tech and diversified investment opportunities.

    Comment?

  2. Cancer trial to match genetic glitches to drugsRead the original story w/Photo

    Yesterday | The Otago Daily Times

    ... free. Drug companies providing treatments include: AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co, Roche's Genentech and Pfizer. Genetic profiling gives doctors a read-out of molecular targets driving a patient's tumors. Often these occur in ...

    Comment?

  3. U.S. Cancer Study to Match Existing Drugs to Genetic MutationsRead the original story w/Photo

    Yesterday | Wall Street Journal

    This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

    Comment?

  4. Large U.S. cancer trial to match genetic glitches to targeted drugsRead the original story w/Photo

    Monday | AlertNet

    ... free. Drug companies providing treatments include: AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co, Roche's Genentech and Pfizer. Genetic profiling gives doctors a read-out of molecular targets driving a patient's tumors. Often these occur in ...

    Comment?

  5. Novel US cancer study will test precision medicineRead the original story w/Photo

    Monday | The New Zealand Herald

    ... poses, and collect information on how they fare. So far, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech and Pfizer have agreed to provide at least 13 drugs, which will be free to study participants.

    Comment?

  6. ASCO 2015: MATCHing, - linquing' just-right drugs to patients as research TAPURs to precisionRead the original story

    Monday | BioWorld

    ... solid tumor, multiple myeloma, or non-Hodgkin's lymphoma. On board to provide drugs are Pfizer Inc., Roche AG unit Genentech, Eli Lilly and Co., Bristol-Myers Squibb Co., and Astrazeneca plc. In TAPUR, doctors will get access to study drugs, ...

    Comment?

  7. ASCO15: Genentech, Exelixis Results for Drug Combo Buoy the Flailing SF BiotechRead the original story

    Sunday May 31 | BioSpace

    ... combination to become a meaningful new treatment option for patients with this type of melanoma. We congratulate Genentech ( RHHBY ) and Roche ( RHHBY ) on two well-run trials, and we look forward to working with them to bring the combination to ...

    Comment?

  8. Radius Health Announces Engagement With For Development Of Abaloparatide Commercialization StrategyRead the original story

    Sunday May 31 | BioSpace

    ... and portfolios. Prior to founding Myrtle Potter & Company, Myrtle was president and chief operating officer of Genentech for five years, where she led the company's launch of seven products, including the blockbuster cancer therapy Avastina . Prior ...

    Comment?

  9. Cooler Buildings Save EnergyRead the original story w/Photo

    Friday May 29 | Scientific American

    ... FRANCISCO, Calif. - In an industrial section of a San Francisco Bay Area suburb, the sleek new office building of Genentech, a biotechnology firm, opened last week. The company knows it will be energy efficient because it is the first project to ...

    Comment?

  10. 23andMe's Plan to Harness Data for Disease TreatmentsRead the original story w/Photo

    Saturday May 23 | Bioscience Technology

    The nearly 10-year-old biotechnology company headquartered in Mountain View, California formed a new therapeutics division, which would be responsible for using 23andMe's large database of genetic information to discover and develop drugs for a litany of diseases, according to Time Magazine. Robert Scheller, an experienced research and development executive from Genentech, was hired by 23andMe in March to run this new part of the firm.

    Comment?

  11. What Genentech's New Building Says About Biotech's Bay Area Economic ImpactRead the original story

    Monday May 25 | BioSpace

    Opening its newest building Thursday, Genentech Inc. rolled out a bunch of facts and figures that underscore the structure's environmental sustainability. What's not so evident, though, is what the biotech giant's second new structure since its 2009 takeover by Roche says about the Bay Area biotech industry.

    Comment?

  12. Contributions of Nonhematopoietic Cells and Mediators to Immune...Read the original story

    Monday May 25 | Toxicological Sciences

    ... of Veterinary Medicine, Mississippi State University, Mississippi St, Mississippi 39762, a Safety Assessment, Genentech, Inc. South San Francisco, California 94080, a Department of Biochemistry and Molecular Biology, Center for Integrative ...

    Comment?

  13. Skin Cancer Investigation Reveals Your Face Is Teeming With Mutant ClonesRead the original story w/Photo

    Friday May 22 | Forbes.com

    ... kinds of cancer. One drug is already on the market for basal cell cancer - vismodegib (trade name: Erivedge), by Genentech. It's currently approved for cancers that can't be treated with surgery. Studies have also shown that it helps people with ...

    Comment?

  14. What Genentech's new building says about biotech's hefty Bay Area economic impactRead the original story w/Photo

    Friday May 22 | Business Journal

    Opening its newest building Thursday, Genentech Inc. rolled out a bunch of facts and figures that underscore the structure's environmental sustainability. What's not so evident, though, is what the biotech giant's second new structure since its 1999 takeover by Roche says about the Bay Area biotech industry.

    Comment?

  15. Genentech's Green Building Could House Up to 1,500 WorkersRead the original story

    Thursday May 21 | BioSpace

    Biotech powerhouse Genentech Inc. is powering down on its energy use, thanks to plugging in to a cross-bay partnership. The South San Francisco-based company on Thursday opened a 255,000-square-foot building, dubbed "Building 35," that leans heavily on energy-saving techniques tested and refined by researchers at the Lawrence Berkeley National Laboratory's FlexLab facility.

    Comment?

  16. Abstract 205: Improving Door to Needle Time for IV Thrombolysis in...Read the original story

    Apr 29, 2015 | Circulation

    ... None. C. Lindauer: None. T. Tolson: None. M. Saheed: None. P. Hill: None. V.C. Urrutia: B. Research Grant; Modest; Genentech, Inc. Clinical trial of IV tPA in wake up stroke (SAIL ON).

    Comment?

  17. Genentech unveils eco-friendly office buildingRead the original story w/Photo

    Thursday May 21 | SFGate

    Sun-blocking fins that look like DNA were just one of the unusual aspects that stood out Thursday when Genentech unveiled Building 35, a 255,000-square-foot office structure that will be the most eco-friendly on its South San Francisco campus. The building was the first to be tested at Lawrence Berkeley National Laboratory 's Flexlab, where workers built a 600-square-foot model of the new building that allowed them to test lighting, heating, ventilation, air conditioning and other energy use.

    Comment?

  18. Genentech's big study: Biotech goes green, thanks to Berkeley labRead the original story w/Photo

    Thursday May 21 | Business Journal

    Biotech powerhouse Genentech Inc. is powering down on its energy use, thanks to plugging in to a cross-bay partnership. The South San Francisco-based company on Thursday opened a 255,000-square-foot building, dubbed "Building 35," that leans heavily on energy-saving techniques tested and refined by researchers at the Lawrence Berkeley National Laboratory's FlexLab facility.

    Comment?

  19. U.S. science leaders to tackle ethics of gene-editing technologyRead the original story

    Monday May 18 | WNFL-AM Green Bay

    ... guidelines and federal regulations of recombinant DNA, the gene-splicing technology that underlay the founding of Genentech and other biotech companies and revolutionized the production of many pharmaceuticals. "We provided leadership in the past on ...

    Comment?

  20. Genentech vets, backed with $217M, take aim at tough brain diseasesRead the original story w/Photo

    Friday May 15 | Business Journal

    A trio of former Genentech Inc. veterans will seek answers for treatment to some of the toughest brain diseases, including Alzheimer's and Lou Gehrig's diseases, in a new company initially funded with $217 million. The leaders of Denali Therapeutics Inc. of South San Francisco are saying little about their scientific approach to new drugs for people with those neurodegenerative diseases, which have been tough to treat.

    Comment?